Biolab will manufacture and sell Roche's antiviral drug in Brazil

Laboratory receives sublicence to produce Xofluza

A Biolab It was chosen by the Medicines Patent Pool (MPP), an organization supported by the UN, to manufacture and market baloxavir marboxil in Brazil, Antiviral Roche Sold under the brand name Xofluza. The information is from Valor Econômico.

The sub-licence was signed by the MPP with the Swiss pharmaceutical company and provides for the selection of manufacturers to manufacture the product. expand access to the medicine in 129 low- and middle-income countries.

The agreement widens the range of drugs for which the Brazilian pharmaceutical company is responsible, It focuses primarily on the segments of cardiology, gynecology, dermatology, pediatrics, central nervous system, angiology, and orthopedics.

“Pandemics do not mark a time for their occurrence and cannot wait for prolonged negotiations. Now we are ready, with a solid productive base, to do our part in Brazil and the region,” he states. Fábio Amorosino, President of Biolab.

Xofluza is an oral antiviral administered in a single dose and recommended by WHO for the treatment of influenza, including prophylaxis after exposure to the virus.

You can also access the article via the link: Biolab will manufacture and sell Roche's antiviral drug in Brazil